Madrigal Pharmaceuticals, Inc. (MDGL) has a consensus analyst rating of Buy, based on 23 analysts covering the stock. Of those, 20 recommend buying, 2 recommend holding, and 1 recommend selling.
The analyst consensus price target for MDGL is $705.67, representing a +34.4% upside from the current price of $524.99. Price targets range from a low of $527.00 to a high of $964.00.
